Astellas and XenoPort Announce Submission of a New Drug Application in Japan
Astellas Pharma Inc. and XenoPort, Inc. have announced that a new drug application (NDA) has been filed with the Pharmaceuticals and Medical Device Agency (PMDA) in Japan for ASP8825 (gabapentin enacarbil), also known as XP13512, as a potential treatment for restless legs syndrome (RLS). The acceptance of filing of the NDA triggers a $5 million milestone payment from Astellas to XenoPort.
For the full story, Click Here
- FDA approves new formulation Vaprisol
- Diabetes drug Victoza Gets FDA Approval
- Mylan receives approval for generic Cytomel
- Watson Pharmaceuticals’ arm gets nod from U.S. FDA for Azurette Tablets
